Overview
- Published March 17 in PLOS Medicine, the multi-stage investigation analyzed thousands of participants from U.S. and Shanghai cohorts using discovery, in silico, and targeted validation phases.
- The final validation tied nine circulating metabolites to incident coronary heart disease, including TMAO, phenylacetyl‑L‑glutamine, indolepropionate, imidazole propionate, and 3‑hydroxybutyrate.
- Adjusted effect sizes were modest, with odds ratios roughly 1.18 to 1.27, positioning the metabolites as potential risk markers rather than proof of causality.
- Most associations held across demographics and lifestyles, though some variation appeared by race, age, obesity status, and follow-up time.
- Authors note assay-coverage limits prevented validating every candidate and emphasize the observational design, calling for mechanistic and interventional studies to test causality and clinical utility.